ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

34128 results sorted by trial registration date.
  • A Controlled Trial Evaluating MindWise Leadership, a Mental Health Training Program for Managers in Nursing and Midwifery

    This project aims to conduct a controlled trial to investigate the effectiveness of MindWise Leadership, an evidence-based mental health training program for people-leaders in nursing and midwifery. This trial will be used to measure whether this training program will improve managers' and leaders' responsive behaviours, preventative behaviours, confidence, knowledge and stigma regarding employee mental health. It also aims to investigate whether any changes are sustained over a 6-month period. The research aims that this research seeks to address are: Primary objective: Evaluate the effectiveness of MindWise Leadership in improving managers’ behaviour regarding employee mental health matters in the workplace Secondary objectives: Evaluate the effectiveness of MindWise Leadership in improving managers’ confidence, attitude, and knowledge regarding employee mental health. Evaluate the effectiveness of MindWise Leadership on reducing employees’ sick leave and medical errors.

  • A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Food on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PNV-8297 in Healthy Volunteers

    In this study, the safety and tolerability of the study treatment, PNV-8297, will be evaluated in healthy volunteers when it is taken with or without a high-calorie meal over 14 days. PNV-8297 is a potential new treatment for Major Depressive Disorder (MDD) which has not been given to humans before. This study aims to test how the body responds to the study drug in a fed or fasted state, and whether it has any undesirable side effects.

  • A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PNV-8297 in Healthy Volunteers

    In this study, the safety and tolerability of the study treatment, PNV-8297, will be evaluated in healthy volunteers when it is taken orally as single dose, or in multiple doses over 14 days. PNV-8297 is a potential new treatment for Major Depressive Disorder (MDD) which has not been given to humans before. This study aims to test how the body responds to the study drug, and whether it has any undesirable side effects.

  • Feasibility, acceptability and appropriateness of a specialist sleep assessment and treatment centre model of care to support sleep disorder management in shift workers

    Sleep disorders are poorly identified and managed in shift workers, and associated with considerable risk to worker health and safety; particularly in the early career years. Recognising the additive effects of unmanaged sleep disorders with shift work schedules and insufficient sleep, unmanaged sleep disorders represent a considerable work health and safety issue which require solutions for organisations repsonsible for rostering and managing fatigue-related hazards. The purpose of this study is to explore feasibility, acceptability and appropriateness of a tailored approach to identifying at-risk early career shift workers, and examining the impacts of supporting help-seeking for safety (risky driving), productivity (absenteeism and presenteeism), burnout and turnover intention.

  • Preventing intra-uterine infection and neonatal sepsis treatment failure in CALD communities: Precision antibiotic therapy through pathogen genomics (observational phase).

    The purpose of this study is to evaluate a new genetic testing method for detecting microbes (including bacteria) during pregnancy. The study will compare this test with the standard laboratory testing currently used in clinical care. We expect that the new test will be acceptable to patients and healthcare professionals and will identify infections at least as well as standard testing, while also providing additional information that may help guide the prevention and treatment of infections in mothers and newborns. The feasibility of using this new testing method in routine antenatal care will be assessed through its performance compared with standard testing, participant feedback, and assessment of the resources and costs required for implementation.

  • IRIES: Immersive virtual Reality during transvaginal ultrasound In people with EndometriosiS — Protocol for a mixed-methods randomised pilot and feasibility trial

    Transvaginal ultrasound is commonly used to assess endometriosis, but the examination can be associated with pain, anxiety and emotional distress. This study aims to find out whether using immersive virtual reality during transvaginal ultrasound is feasible, acceptable and safe for women with endometriosis. Twenty women will be randomly assigned to have either a standard transvaginal ultrasound or a transvaginal ultrasound while using immersive virtual reality. The study will assess whether participants can be recruited and retained, whether virtual reality can be successfully used during the examination, and whether the study procedures are practical and acceptable. It will also explore participants' experiences of pain, anxiety, distress and control to help inform the design of a larger future trial.

  • Phase 1b study evaluating the safety and efficacy of Dendritic cell Immune activation combined with Venetoclax and Azacitidine as frontline therapy for patients with newly diagnosed acute myeloid leukaemia unfit for intensive chemotherapy

    .This study is evaluating the safety and efficacy of Dendritic cell Immune activation combined with Venetoclax and Azacitidine as frontline therapy for patients with newly diagnosed acute myeloid leukaemia unfit for intensive chemotherapy Who is it for? You may be eligible to join this study if you are aged 18 years or above, have been diagnosed with acute myeloid leukaemia unfit for intensive chemotherapy and receiving Venetoclax-Azacitidine as frontline induction therapy Study details All participants will receive Vididencel (an off-the-shelf allogeneic dendritic cell immune activator) in combination with standard-of-care Venetoclax and Azacitidine. Vididencel treatment regimen consists of four priming doses administered on Day 1 and 15 of Cycles 1 and 2 followed by two booster doses administered on Day 1 of Cycles 4 and 5. Participants will be assessed for safety and tolerability using clinical examination, blood tests, vital sign monitoring, reporting of adverse events for the duration of their treatment over the first 6 months. Measurable Residual Disease will be assessed using examination of blood cells and molecular markers during each cycle until the end of the study over 3 years

  • Australian Atypical Parkinsonism Project (A2P) Biobank

    The purpose of the A2P biobank is to collect repeated clinical measures, MRI imaging and biological samples from patients with progressive supranuclear palsy, multiple system atrophy, corticobasal syndrome as well as Parkinson’s disease. Allowing future researchers to potentially find new tests for earlier and more accurate diagnosis, accurate predictors of disease progression and effective new treatments.

  • Phase 1a study to assess safety an tolerability of a single ascending dose of MMB-003 in Healthy Participants.

    This first-in-human, double-blind, placebo-controlled phase 1a study in healthy participants designed to assess the safety and tolerability of MMB-003. This study consists of 2 parts: 1. Part 1 will assess single ascending doses (SAD) in 3 cohorts of healthy male and female participants. Each cohort will consist of 4 participants (3 active:1 placebo) across both parts of the study; thus, a total of 12 healthy volunteers and up to 16 UC participants are planned to be enrolled.

  • Phase 2a, Placebo Controlled Single-Center Study to Evaluate the Safety and Tolerability of Multiple Ascending Doses of study drug MMB-003 in Participants with Ulcerative Colitis (UC).

    This first-in-human, double-blind, placebo-controlled phase 2a study in participants with UC designed to assess the safety and tolerability of MMB-003. This study consists of 2 parts. Part 2 will assess multiple ascending doses (MAD) in 3 cohorts of male and female participants with UC. An additional 4 participants may be enrolled in the study in any of the MAD cohorts once the safety data has been obtained and the dose level has been cleared.

Tags:
  • Finding clinical trials